Linie 30 Florisdorf, Vienna

With all the frequent attention on lung cancer of late – mostly on the most common form, non-small cell lung cancer – it’s easy to forget small cell lung cancer (SCLC) in the rush to highlight new developments.

It’s time to talk turkey about old and new agents in the quest to improve outcomes for people with this dismal disease.

The good news is there are also a raft of scientific developments emerging, which may potentially help us better identify discrete subsets and enable the matching of appropriate regimens to the underlying biology.

At the World Conference in Lung Cancer this week in Vienna we’ve been following the numerous trials (and tribulations!) of progress in this niche, with a look at several key readouts through the lens of a thoracic lung cancer specialist.

What does he have to say and where are things heading next for the field?

To find out more, check out the interview below…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by